共 187 条
[1]
Amin S(2020)Usage patterns of short-acting β(2)-agonists and inhaled corticosteroids in asthma: a targeted literature review J Allergy Clin Immunol Pract 8 2556-64.e8
[2]
Soliman M(2019)Understanding reliever overuse in patients purchasing over-the-counter short-acting beta(2) agonists: an Australian community pharmacy-based survey BMJ Open 9 4190-208
[3]
McIvor A(2020)Asthma-related health outcomes associated with short-acting β(2)-agonist inhaler use: an observational UK study as part of the SABINA global program Adv Ther 37 1901872-76
[4]
Cave A(2020)Overuse of short-acting β(2)-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme Eur Respir J 55 1865-87
[5]
Cabrera C(2018)Inhaled combined budesonide-formoterol as needed in mild asthma N Engl J Med 378 1579-2022
[6]
Azzi EA(2014)Asthma control in the United States, 2008–2010: indicators of poor asthma control J Allergy Clin Immunol 133 00032-6
[7]
Kritikos V(2022)Is overreliance on short-acting β(2)-agonists associated with health risks in the older asthma population? ERJ Open Res 8 501-s30
[8]
Peters MJ(1992)The use of beta-agonists and the risk of death and near death from asthma N Engl J Med 326 6-73
[9]
Price DB(2021)The impact of moderate and severe asthma exacerbations on quality of life: a post hoc analysis of randomised controlled trial data J Patient Rep Outcomes 5 S19-82
[10]
Srour P(2022)2020 NAEPP guidelines update and GINA 2021-asthma care differences, overlap, and challenges J Allergy Clin Immunol Pract 10 343-35